Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. - Wikidata - awgldk - TriplyDB

Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer.

Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer.

http://www.wikidata.org/entity/Q34389542

about

Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease Candidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitors Emerging targets in neuroinflammation-driven chronic pain Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung Matrix metalloproteinases in tumorigenesis: an evolving paradigm.Pharmacokinetics and safety assessments of high-dose and 4-week treatment with S-3304, a novel matrix metalloproteinase inhibitor, in healthy volunteers.Proteinases in the joint: clinical relevance of proteinases in joint destruction Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study.Antiprotease therapy in cancer: hot or not?Tumor cell expression of MMP3 as a prognostic factor for poor survival in pancreatic, pulmonary, and mammary carcinoma The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin.Development of growth inhibitory agents in urological and other malignancies.Emerging drugs for the treatment of soft tissue sarcomas.Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein shedding Cetuximab in non-small cell lung cancer.Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab.Stromal Modulators of TGF-β in Cancer.Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer.Is response rate increment obtained by molecular targeted agents related to survival benefit in the phase III trials of advanced cancer?Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma.Personalized therapies in the cancer "omics" era Targeting the Fas/FasL signaling pathway in cancer therapy.Factors affecting efficacy and safety of add-on combination chemotherapy for non-small-cell lung cancer: a literature-based pooled analysis of randomized controlled trials.Pleural effusion in lung cancer: more questions than answers.Matrix metalloproteinase-2 as a target for head and neck cancer therapy.Targeting angiogenesis for treatment of human cancer Targeting matrix metalloproteinase activity and expression for the treatment of viral myocarditis.Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.Intricate Functions of Matrix Metalloproteinases in Physiological and Pathological Conditions.A Chemically Modified Curcumin (CMC 2.24) Inhibits Nuclear Factor κB Activation and Inflammatory Bone Loss in Murine Models of LPS-Induced Experimental Periodontitis and Diabetes-Associated Natural Periodontitis.The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies.

P2860

Q24200518-F254B288-5F10-4688-A41A-ADD61C1D8939 Q24243664-B7DA152A-3F95-4251-AB67-4DC0EA72D465 Q26830522-BFA9C0A1-89AC-4617-8F41-0B202A3A7784 Q28242435-B1C5644E-4FDC-47D8-9E44-ED3B9E8B7D2C Q28727262-9D1D0EFF-49E2-48D4-88A2-829199A484ED Q33619924-50E2C692-FFF6-43E0-BF1B-7802A0E072B0 Q33748738-B9AC633D-4F3C-498F-A0F6-F92DC766C155 Q34199345-15C538C6-6E63-4E50-AE72-D85D4E8FC7EE Q36025140-F63FEDAE-0FE2-4E7F-B249-416D4B3B1F07 Q36401848-43A074B5-7623-4714-A2C2-EECDC75F000E Q36401915-8B17C835-BBD0-494B-B5E9-437A206467D9 Q36407244-328A7E78-6CBA-4CEA-8C1B-B9B378D27908 Q36430125-97D95296-1BAF-4D34-9ECF-372E9405CB41 Q36494563-798C90E6-8BCC-414E-9AA5-3970E9DF6299 Q36530430-C54AA602-F790-4934-84A8-173CACE1B971 Q36758596-A021BD21-D1BC-4D16-90E8-BDDEC4A0BB37 Q36804675-6FC7DFD2-E111-464E-8D58-05C1FE7AA8EE Q37032651-41BA6BE2-2D9A-4278-8642-DC5CA3593F43 Q37290520-B8D10D3C-B836-48A6-869A-D25A990FFC45 Q37628179-406AEC76-3283-4E55-A55E-2C5818F76D70 Q37665014-7FE96E96-FF33-42A0-836D-F2B9DEA6D561 Q37671970-D5348228-83E3-4930-B858-C14530ABDFB4 Q37736273-B910ED09-F1B0-4A2D-814C-31A7DDB62CA5 Q37776547-367B8341-23EB-40E6-BF3B-2CBE3EEF9ACF Q37975245-CDA699FB-D416-48DD-A749-35440C464A3A Q37986608-3A6CD22B-E5BD-4CCE-8F1F-7FD079B1945C Q38009999-DECE8A06-F58F-41F7-A01A-0E1268F4B2B6 Q38068476-591316EB-BC43-4792-9E76-C1A814FFA713 Q38125442-310D6EE2-DB19-4F55-AAF5-F8E67AEC42AE Q38174997-8BD3C9C4-01D8-4A0B-A145-7F62E5B37D75 Q38725320-DAB21BF1-4B83-4E55-ABE2-9FAE17A668FE Q38836225-2B7E4C24-7D7B-45C8-8E1C-B9C6710A4C92 Q52866845-7AFE5408-F622-49F2-A4D3-ACC7BC725965 Q54215275-A0420DFB-4DC4-485B-AEF1-4BEFCA6E3257

P2860

Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer.

http://www.wikidata.org/entity/Q34389542

description

2005 nî lūn-bûn

@nan

2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Phase III study of matrix meta ...... in non-small-cell lung cancer.

@ast

Phase III study of matrix meta ...... in non-small-cell lung cancer.

@en

Phase III study of matrix meta ...... in non-small-cell lung cancer.

@nl

type

label

Phase III study of matrix meta ...... in non-small-cell lung cancer.

@ast

Phase III study of matrix meta ...... in non-small-cell lung cancer.

@en

Phase III study of matrix meta ...... in non-small-cell lung cancer.

@nl

prefLabel

Phase III study of matrix meta ...... in non-small-cell lung cancer.

@ast

Phase III study of matrix meta ...... in non-small-cell lung cancer.

@en

Phase III study of matrix meta ...... in non-small-cell lung cancer.

@nl

P1433

Q34389542-F600D7A7-C85B-4230-9969-FE9AC0AA2644

P1476

Q34389542-06C233E3-F277-4626-838D-09D7E63C438A

P2093

Q34389542-0DE60633-1D07-4BC2-87C2-134D48328BDD

Q34389542-16161EF0-B700-4E0E-A3B8-EDC4C40CF116

Q34389542-524F975C-778A-43E7-8D5C-1081FBA97DA8

Q34389542-6D72D908-C58D-4FC2-A7D3-B94B24182695

Q34389542-7E6CE08B-5A7B-4725-8811-C3E26DF7617B

Q34389542-80B02C27-96D2-4FA8-A575-EFBB7D12AA7E

Q34389542-86FDAC51-3931-4671-9128-B13F5E91C1B8

Q34389542-A1C942E0-E12B-44E1-90AB-0F196EA5ECFD

Q34389542-CA793FF9-7697-4E9B-8540-51DECB3516C3

Q34389542-D01B3C2F-1FEC-405C-A13A-01E7C9FD818A

P304

Q34389542-D7C5870B-E857-4A7B-83AE-DA1CDB9BFCF6

P31

Q34389542-683F753D-AD06-4AED-969E-347FC2FA5269

P356

Q34389542-B9A1B358-0FC7-48F3-86B3-F429BD16EC6E

P407

Q34389542-0B2576E0-8942-4AA9-AC7F-15334F266268

P433

Q34389542-98D4D73E-D443-4ACF-A3F1-20C938C37238

P478

Q34389542-242120B4-7ACB-487F-AEEB-2283DED7329B

P577

Q34389542-5C6D0887-1E0A-40A1-A34D-2A057E77BD04

P5875

Q34389542-EA8A0792-F3B3-4EE7-87E0-ECA30390DEA0

P698

Q34389542-F9C261FF-A135-40EB-B4DF-1E1D7ECD61DE

P921

Q34389542-4A30E6C6-98E2-4297-A9E2-4F03983EEC9D

P356

JCO.2005.03.170

P1433

Journal of Clinical Oncology

P1476

Phase III study of matrix meta ...... in non-small-cell lung cancer.

@en

P2093

Allan Price

http://www.w3.org/2001/XMLSchema#string

Carol Penning

http://www.w3.org/2001/XMLSchema#string

Donald Bissett

http://www.w3.org/2001/XMLSchema#string

Elva Mazabel

http://www.w3.org/2001/XMLSchema#string

Frances A Shepherd

http://www.w3.org/2001/XMLSchema#string

J von Pawel

http://www.w3.org/2001/XMLSchema#string

Ken J O'Byrne

http://www.w3.org/2001/XMLSchema#string

Marianne Nicolson

http://www.w3.org/2001/XMLSchema#string

Mary A Collier

http://www.w3.org/2001/XMLSchema#string

Min H Zhang

http://www.w3.org/2001/XMLSchema#string

P304

842-849

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.03.170

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8049831

http://www.w3.org/2001/XMLSchema#string

P698

15681529

http://www.w3.org/2001/XMLSchema#string

P921